一个新的药物组合显示,先进的PD-L1阳性三阴性乳腺癌患者的存活率有所改善。 A new drug combo shows improved survival for patients with advanced PD-L1 positive triple-negative breast cancer.

一种结合Trodelvy和Keytruda的新的治疗方法显示,对患有高度或转移性三负性乳腺癌(TNBC)的病人有重大好处,PD-L1呈阳性。 A new treatment combining Trodelvy and Keytruda shows significant benefits for patients with advanced or metastatic triple-negative breast cancer (TNBC) that is PD-L1 positive. 第3阶段ASCENT-04/KEYNOTE-D19研究发现,这种结合将无进展存活率提高到了11.2个月,而标准化疗加Keyturda为7.8个月。 The phase 3 ASCENT-04/KEYNOTE-D19 study found that this combination improved progression-free survival to 11.2 months compared to 7.8 months with standard chemotherapy plus Keytruda. 这种治疗可能成为这种形式的乳腺癌患者的新标准。 This treatment could become the new standard for patients with this form of breast cancer.